Eli Silvert

Eli Silvert

Auto-generated profile, based on publicly available information

Eli Silvert

Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2021 in Med
Verified
Journal Article
Open access
APArjun Puranik
Arjun Puranik
PLPatrick Lenehan
Patrick Lenehan
ESEli Silvert
Eli Silvert
MNMichiel J.M. Niesen
Michiel J.M. Niesen
JCJuan Corchado-Garcia
Juan Corchado-Garcia
VSVenky Soundararajan
Venky Soundararajan
MRNA coronavirus disease 2019 (COVID-19) vaccines are safe and effective, but increasing reports of breakthrough infections highlight the need to vigilantly monitor and compare the effectiveness of these vaccines. We retrospectively compared protection against symptomatic infection conferred by mRNA-1273 and BNT162b2 at Mayo Clinic sites from December 2020 to September 2021. We used a test-negative case-control design to estimate vaccine effectiveness (VE) and to compare the odds of symptomatic infection after full vaccination with mRNA-1273 versus BNT162b2, while adjusting for age, sex, race, ethnicity, geography, comorbidities, and calendar time of vaccination and testing. Both vaccines were highly effective over the study duration (VEmRNA-1273: 84.1%, 95% confidence interval [CI]: 81.6%–86.2%; VEBNT162b2: 75.6%, 95% CI: 72.2%–78.7%), but their effectiveness was reduced during July–September (VEmRNA-1273: 75.6%, 95% CI: 70.1%–80%; VEBNT162b2: 63.5%, 95% CI: 55.8%–69.9%) as compared to December–May (VEmRNA-1273: 93.7%, 95% CI: 90.4%–95.9%; VEBNT162b2: 85.7%, 95% CI: 81.4%–88.9%). Adjusted for demographic characteristics, clinical comorbidities, time of vaccination, and time of testing, the odds of experiencing a symptomatic breakthrough infection were lower after full vaccination with mRNA-1273 than with BNT162b2 (odds ratio: 0.60; 95% CI: 0.55–0.67). Both mRNA-1273 and BNT162b2 strongly protect against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is imperative to continue monitoring and comparing available vaccines over time and with respect to emerging variants to inform public and global health decisions. This study was funded by nference.

1 April 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
HBHannah Barman
Hannah Barman
SVSriram Venkateswaran
Sriram Venkateswaran
ASAntonio Del Santo
Antonio Del Santo
UYUnice Yoo
Unice Yoo
ESEli Silvert
Eli Silvert
RMRajat Mohindra
Rajat Mohindra
PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in the real-world data setting is critical for characterizing the benefit/risk profile of ICI therapies beyond the clinical trial population. Diagnosis codes, such as International Classification of Diseases codes, do not comprehensively illustrate a patient's care journey and offer no insight into drug-irAE causality. This study aims to capture the relationship between ICIs and irAEs more accurately by using augmented curation (AC), a natural language processing–based innovation, on unstructured data in electronic health records. METHODS: In a cohort of 9,290 patients treated with ICIs at Mayo Clinic from 2005 to 2021, we compared the prevalence of irAEs using diagnosis codes and AC models, which classify drug-irAE pairs in clinical notes with implied textual causality. Four illustrative irAEs with high patient impact—myocarditis, encephalitis, pneumonitis, and severe cutaneous adverse reactions, abbreviated as MEPS—were analyzed using corticosteroid administration and ICI discontinuation as proxies of severity. RESULTS: For MEPS, only 70% (n = 118) of patients found by AC were also identified by diagnosis codes. Using AC models, patients with MEPS received corticosteroids for their respective irAE 82% of the time and permanently discontinued the ICI because of the irAE 35.9% (n = 115) of the time. CONCLUSION: Overall, AC models enabled more accurate identification and assessment of patient impact of ICI-induced irAEs not found using diagnosis codes, demonstrating a novel and more efficient strategy to assess real-world clinical outcomes in patients treated with ICIs.

4 July 2023 in American Journal of Hematology
Verified
Journal Article
Open access
ESEli Silvert
Eli Silvert
LHLaura Hester
Laura Hester
EREshwan Ramudu
Eshwan Ramudu
CPColin Pawlowski
Colin Pawlowski
BKBritte Kranenburg
Britte Kranenburg
ADAngela Dispenzieri
Angela Dispenzieri

28 March 2026 in Clinical Trials
Verified
Journal Article
Open access
EEEzekiel J Emanuel
Ezekiel J Emanuel
SLSamantha Lopez-Rico
Samantha Lopez-Rico
MOMerjan Lijerón Ozisik
Merjan Lijerón Ozisik
ESEli Silvert
Eli Silvert
Background/Aims: Informed consent forms are an essential component of ethical clinical research. However, they are failing. They are long, legalistic, and written at an 11th-grade reading level. Consequently, many participants have poor comprehension of the research they are considering. Our objective is to assess participant comprehension and satisfaction across three informed consent forms of different lengths and formats including one based on the Food and Drug Administration’s (FDA) 2024 draft summary template. Methods: In total, 334 healthy participants from AmeriSpeak’s online survey panel were recruited via email and AmeriSpeak’s member portal, oversampling less educated individuals and those from racial and ethnic minority groups. Participants were randomized to three informed consent forms—long, medium, and short—and were asked to imagine hypothetically being a patient considering joining a study. They were given a brief introduction on the purpose of informed consent forms and of this project’s goal to evaluate comprehension, satisfaction, and willingness to join the described hypothetical study but were not told the hypothesis or that there were three different informed consent forms. The long informed consent form (21 pages) was used in an actual international Bristol Myers Squibb study concerning a stroke prevention regimen. The long informed consent form contained longer paragraphs and lists and was written just below an 11th-grade level. The long informed consent form was modified to create the medium (14 pages) and short informed consent forms (3 pages), which both used simpler words, shorter sentences, less passive voice, tables, and other patient-friendly edits to achieve below sixth-grade reading levels. The short informed consent form was adapted from the Food and Drug Administration’s 2024 draft summary template. Results: The medium informed consent form (mean score of 79.3%) scored significantly higher on comprehension than the long informed consent form (65.7% mean score, p < 0.001) or the short informed consent form (69.3% mean score, p = 0.006). Compared to the long informed consent form, fewer medium informed consent form participants found their informed consent form “too long” or “too detailed.” Compared to the long and medium informed consent forms, more short informed consent form participants reported wanting more information on study procedures. Conclusion: The medium-length informed consent form, written at a sixth-grade reading level, with shorter words and sentences, tables, and enhanced formatting, produced significantly better comprehension than longer or shorter informed consent forms. The short informed consent form produced the same level of comprehension as a long informed consent form used in approved clinical trials. Researchers, pharmaceutical companies, and institutional review boards should adopt these informed consent form modifications to increase participant comprehension and satisfaction.